Patents by Inventor Stefanie Mandl

Stefanie Mandl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF MVA TO TREAT PROSTATE CANCER
    Publication number: 20110008386
    Abstract: The invention relates to compositions, kits, and methods for cancer prophylaxis and therapy using recombinant MVA viruses encoding tumor-associated antigens, such as PSA and PAP. The recombinant MVA viruses can induce B- and T-cell responses. The recombinant MVA viruses can be administered prior to, at the same time as, or after a taxane.
    Type: Application
    Filed: August 30, 2010
    Publication date: January 13, 2011
    Inventors: Alain DELCAYRE, Reiner Laus, Stefanie Mandl, Ryan Blair Rountree, Fatema Legrand
  • METHODS FOR TREATING CANCER WITH MVA
    Publication number: 20110008294
    Abstract: The invention relates to compositions, kits, and methods for cancer therapy using recombinant MVA viruses encoding a tumor-associated antigen, such as HER-2, particularly in combination with taxanes. The taxanes can be administered prior to, at the same time as, or after the recombinant MVA virus.
    Type: Application
    Filed: August 31, 2010
    Publication date: January 13, 2011
    Inventors: Alain DELCAYRE, Reiner Laus, Stefanie Mandl
  • Use of MVA to treat prostate cancer
    Patent number: 7867483
    Abstract: The invention relates to compositions, kits, and methods for cancer prophylaxis and therapy using recombinant MVA viruses encoding tumor-associated antigens, such as PSA and PAP. The recombinant MVA viruses can induce B- and T-cell responses. The recombinant MVA viruses can be administered prior to, at the same time as, or after a taxane.
    Type: Grant
    Filed: October 16, 2008
    Date of Patent: January 11, 2011
    Assignee: BN Immunotherapeutics, Inc.
    Inventors: Alain Delcayre, Reiner Laus, Stefanie Mandl, Ryan Blair Rountree, Fatema Legrand
  • Methods for treating cancer with a recombinant MVA expressing HER-2
    Patent number: 7807146
    Abstract: The invention relates to compositions, kits, and methods for cancer therapy using recombinant MVA viruses encoding a tumor-associated antigen, such as HER-2, particularly in combination with taxanes. The taxanes can be administered prior to, at the same time as, or after the recombinant MVA virus.
    Type: Grant
    Filed: October 5, 2007
    Date of Patent: October 5, 2010
    Assignee: BN Immunotherapeutics, Inc.
    Inventors: Alain Delcayre, Reiner Laus, Stefanie Mandl
  • USE OF MVA TO TREAT PROSTATE CANCER
    Publication number: 20090104225
    Abstract: The invention relates to compositions, kits, and methods for cancer prophylaxis and therapy using recombinant MVA viruses encoding tumor-associated antigens, such as PSA and PAP. The recombinant MVA viruses can induce B- and T-cell responses. The recombinant MVA viruses can be administered prior to, at the same time as, or after a taxane.
    Type: Application
    Filed: October 16, 2008
    Publication date: April 23, 2009
    Inventors: Alain Delcayre, Reiner Laus, Stefanie Mandl, Ryan Blair Rountree, Fatema Legrand
  • Methods for treating cancer with MVA
    Publication number: 20080213302
    Abstract: The invention relates to compositions, kits, and methods for cancer therapy using recombinant MVA viruses encoding a tumor-associated antigen, such as HER-2, particularly in combination with taxanes. The taxanes can be administered prior to, at the same time as, or after the recombinant MVA virus.
    Type: Application
    Filed: October 5, 2007
    Publication date: September 4, 2008
    Inventors: Alain Delcayre, Reiner Laus, Stefanie Mandl